Contact
    Start Publications Poly(caprolactone)-Based Coatings on 3D-Printed Biodegradable ...
    ←  Publication Finder
    Attension

    Poly(caprolactone)-Based Coatings on 3D-Printed Biodegradable Implants: A Novel Strategy to Prolong Delivery of Hydrophilic Drugs

    Year: 2020

    Journal: Mol. Pharm., Volume 17, SEP 8, page 3487–3500

    Authors: Stewart, Sarah A.; Dominguez-Robles, Juan; McIlorum, Victoria J.; Gonzalez, Zoilo; Utomo, Emilia; Mancuso, Elena; Lamprou, Dimitrios A.; Donnelly, Ryan F.; Larraneta, Eneko

    Organizations: Wellcome TrustWellcome TrustEuropean Commission [UNS40040, WT094085MA]; Department for the Economy (Northern Ireland) studentship

    Keywords: poly(caprolactone) coatings; poly(ethylene glycol); implantable drug delivery; hydrophilic drugs; additive manufacturing; 3D printing; fused filament fabrication

    Implantable devices are versatile and promising drug delivery systems, and their advantages are well established. Of these advantages, long-acting drug delivery is perhaps the most valuable. Hydrophilic compounds are particularly difficult to deliver for prolonged times. This work investigates the use of poly(caprolactone) (PCL)-based implant coatings as a novel strategy to prolong the delivery of hydrophilic compounds from implantable devices that have been prepared by additive manufacturing (AM). Hollow implants were prepared from poly(lactic acid) (PLA) and poly(vinyl alcohol) (PVA) using fused filament fabrication (FFF) AM and subsequently coated in a PCL-based coating. Coatings were prepared by solution-casting mixtures of differing molecular weights of PCL and poly(ethylene glycol) (PEG). Increasing the proportion of low-molecular-weight PCL up to 60% in the formulations decreased the crystallinity by over 20%, melting temperature by over 4 degrees C, and water contact angle by over 40 degrees, resulting in an increased degradation rate when compared to pure high-molecular-weight PCL. Addition of 30% PEG to the formulation increased the porosity of the formulation by over 50% when compared to an equivalent PCL-only formulation. These implants demonstrated in vitro release rates for hydrophilic model compounds (methylene blue and ibuprofen sodium) ranging from 0.01 to 34.09 mg/day, depending on the drug used. The versatility of the devices produced in this work and the range of release rates achievable show great potential. Implants could be specifically developed in order to match the specific release rate required for a number of drugs for a wide range of conditions.
    View publication